Exposure to stress is increasingly recognized as a determinant of vulnerability to substance use disorder (SUD). Stress has been implicated at all points in the SUD trajectory, from the initiation of drug taking, to the maintenance of chronic use, the compulsive behavior that characterizes addiction and the propensity to relapse after a period of abstinence, making recovery a challenge. Although there are many facets of stress that determine its influence, including the type of stressor and its duration, a critical factor is the timing of stressor exposure with respect to brain development. Events occurring during critical windows of development can alter the blueprint of gene expression and shape neural substrates and circuits in ways that have enduring effects on behavior. Notably, the major mental illnesses are thought to arise from maladaptive brain development resulting from early life events and SUD is among these. An additional consideration with SUD is that early life exposure to drugs of abuse can program the development of stress response systems in a manner that can further contribute to a downward cycle of maladaptive behavior. Given the current SUD crisis and an increasing recognition of the potential impact of stress-developmental interactions in determining the trajectory of brain disorders, we at the National Institute on Drug Abuse were inspired to bring together experts in the field to review basic and human studies on this topic.

At a basic level, the paper by Tsai et al. (*The cellular basis of fetal endoplasmic reticulum stress and oxidative stress in drug-induced neurodevelopmental deficits*) describes how prenatal exposure to drugs of abuse can initiate cellular stress responses that have negative consequences for neural proliferation, differentiation and microglial function that affect behavior in the long term. Animal and human studies reviewed by Conradt et al. (*Early life stress and environmental influences on the neurodevelopment of children with prenatal opioid exposure*) reinforce these cellular outcomes with prenatal exposure to opioids. This review discusses the complexity of layering maternal stress over prenatal opioid exposure and the consequences of potential alterations in the programming of stress response systems. Complications associated with the neonatal opioid withdrawal syndrome (NOWS), a pharmacologically induced stressor that is specific to prenatal opioid exposure are discussed. Harder and Murphy (*Early life opioid exposure and potential long-term effects*) further the discussion of behavioral and cognitive consequences of NOWS in their review of animal and human studies. They review findings on the potential role of endogenous opioids as contributors to NOWs and introduce interventions for improving outcomes. Horn et al. *(Neuroendocrine and immune pathways from pre- and perinatal stress to substance abuse)* review animal and human studies that introduce mechanisms through which prenatal and perinatal stress can produce an enduring dysregulation of neuroendocrine and neuroimmune systems via fetal programming that enhances the risk for substance abuse and addiction. A theme that cuts across several reviews is that drugs of abuse initiate a cycle of stress dysregulation that then increases vulnerability to addiction. Wemm and Sinha *(Drug-induced stress responses and addiction risk and relapse*) take on the acute and chronic effects of different drugs of abuse on peripheral and central stress response systems in humans. Their review underscores how stressors and drugs of abuse feed a cycle of dysregulation of homeostasis.

Stressors of a social nature are prevalent for humans. Findings from animal and human studies reviewed by Andersen (*Stress, sensitive periods, and substance abuse*) highlight the relevance of stress in early life when parental bonds are developing and during adolescence, when extra-familial social contacts prevail. Rutherford and Mayes (*Parenting stress: a novel mechanism of addiction vulnerability*) examine the impact of parenting stress on SUD vulnerability of adults caring for young children. Modeling of social stress in animals is essential for elucidating neural substrates that link social stress to SUD. Förster et al. (*Negative consequences of early-life adversity on substance use as mediated by corticotropin-releasing factor modulation of serotonin activity*) review three different rodent models of social stress and discuss how findings from these approaches are illuminating interactions between the stress-related neuropeptide, corticotropin-releasing factor (CRF), serotonin and the dopamine reward system as mechanisms that link social stress and SUD. Likewise, Newman et al. (*Social defeat stress and escalation of cocaine and alcohol consumption: Focus on CRF*) note a role for CRF effects on dopaminergic system in the ability of social stress to promote cocaine and alcohol self-administration. An important conclusion of their review, which compares the effects of social stress in rodents on cocaine, alcohol and opioid self-administration, is that the consequences of the same stressor do not generalize across all drugs of abuse. Although most studies of animal models of stress use rodents, valuable data is emerging from studies using non-human primates and Wakeford et al. *(*[A review of nonhuman primate models of early life stress and adolescent drug abuse](https://www.sciencedirect.com/science/article/pii/S235228951830033X){#intref0010}*)* review some of these data and the advantages of this model. The importance of sex, social hierarchy and coping strategy as determinants of stress effects are highlighted here and the role of serotonin is reinforced. In an experimental report using an inclusivity/exclusivity task, Hanlon et al. (*Brain activity associated with social exclusion overlaps with drug-related frontal-striatal circuitry in cocaine users: A pilot study*) show how activity in brain regions associated with emotional regulation and negative affect is increased in cocaine dependent individuals exposed to social stress. Social stressors come in many forms and Parent et al. ([Stress and substance use among sexual and gender minority individuals across the lifespan](https://www.sciencedirect.com/science/article/pii/S2352289518300237){#intref0015}) address the topic of how the unique social stressors experienced by sexual and gender minority individuals contribute to substance abuse vulnerability. The themes of individual differences in coping strategies and stress reactivity are visited in the reviews by Chaplin et al. (*Stress reactivity and the developmental psychopathology of adolescent substance use*) and Cichetti and Handley (*Child maltreatment and the development of substance use and disorder*) who both discuss the use of a developmental psychopathology framework to understand pathways from early life adversity to substance abuse.

Several of the reviews focus on potential treatments and interventions. Greenwald (*Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework*) uses an affective/motivation systems framework to predict anti-stress therapies that may be effective based on their role on dimensions within this framework. Roos et al. *(Leveraging translational neuroscience to inform early intervention and addiction prevention for children exposed to early life stress)* take a translational neuroscience approach to discuss different interventions that could mitigate the effects of early life stress on substance abuse vulnerability by decreasing stress and enhancing self-regulation in children with early life stress exposure. Targets for pharmacological or neuromodulation therapy are suggested by Mackenzie et al. *(Sex differences in stress-related alcohol use)* in their comprehensive review of brain regions and neural substrates that have been implicated in stress-related alcohol abuse disorder (many of which generalize to abuse of other drugs). Along with others in this issue, this review of the human literature emphasizes sex differences in stress responsivity and patterns of substance abuse, and evidence that females are more likely to abuse alcohol and other drugs to cope with stress. They highlight biological mechanisms underlying the distinctions and put emphasis on sex-specific treatments. The importance of sex-specific pharmacologic effects is also the topic of the review by Strong and Kabbaj (*On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods*). Here they discuss animal and human data that shed light on how ketamine, a novel therapy for treatment resistant depression that may engage reward circuits, may have distinct abuse potential and cognitive impairments depending on sex and age.

Finally, Hoffman et al. (*Stress exposures, neurodevelopment and health measures in the ABCD study*) introduce the expansive and collaborative NIH initiative that is the largest long-term study of brain development and child health. The Adolescent Brain Cognitive Development (ABCD) study is collecting demographic, socioeconomic, mental health, physiological, genetic, cognitive, and brain imaging data from more than 11,000 children around the country beginning at age 9--10 repeatedly for a decade. These data are being released annually to the scientific community through the NIMH Data Archive (<https://data-archive.nimh.nih.gov/abcd>) to advance our understanding of how stress in early life and adolescence shapes the trajectory towards or away from substance abuse.

Together, the reviews in this issue highlight how advances in neuroscience, pharmacology, psychology and social sciences are being integrated to understand the role of stress in the complex etiology of substance abuse and provide avenues for prevention and treatment.
